The University of Antwerp is a dynamic, forward-thinking, European university. We offer an innovative academic education to more than 20000 students, conduct pioneering scientific research and play an important service-providing role in society. We are one of the largest, most international and most innovative employers in the region. With more than 6000 employees from 100 different countries, we are helping to build tomorrow's world every day. Through top scientific research, we push back boundaries and set a course for the future – a future that you can help to shape. The Faculty of Pharmaceutical, Biomedical and Veterinary Sciences at the University of Antwerp is seeking to fill a full-time (100%) vacancy in the Department of Pharmaceutical Sciences for a postdoctoral researcher in chemical biology and drug discovery in the area of protease research. Background research groups: You will be working in the research group Medical Biochemistry (LMB) in close collaboration with Medicinal Chemistry (UAMC) and Molecular Imaging and Radiology (MIRA) on selective and potent Granzyme B ligands, binding mode characterization and transformation into activity-based probes. LMB closely collaborates with UAMC that has a strong track record in the discovery and characterization of potent and specific protease inhibitors, ligands and probes. The collaboration with MIRA enables translational use of these compounds and moving leads closer to the clinic. This research line is supported by multiple international collaborations and European grants. Research topic: Granzyme B (GRZB) is the most abundant protease present in the granules of cytotoxic immune cells and plays a key role in targeted cancer cell killing by the immune system. In tumors, the amount of GRZB that is secreted by activated immune cells, is inversely correlated with the degree of immunosuppression. Therefore, GRZB is quantified in tumor biopsies of patients treated with immune checkpoint inhibitors. Moreover, significant research effort is going to the discovery of Positron Emission Tomography (PET)-probes that allow minimally-invasive imaging of GRZB. This approach is also relevant for CAR T and CAR NK cell therapy, where the amount of released GRZB correlates with therapy response. Within a Marie Curie Doctoral Network ‘OncoProTools’ we are conducting research on novel GRZB activity-based probes. You will contribute to this effort in the following ways:
Next to experimental research, you will apply for a postdoctoral fellowship via FWO (‘junior postdoctoral fellowship’) and/or HORIZON-MSCA-postdoctoral fellowship in the 2025 call (submission in September 2025 for MSCA and December 2025 for FWO fellowship). Profile
What we offer
Want to apply?
The University of Antwerp received the European Commission’s HR Excellence in Research Award for its HR policy. We are a sustainable, family-friendly organisation which invests in its employees’ growth. We encourage diversity and attach great importance to an inclusive working environment and equal opportunities, regardless of gender identity, disability, race, ethnicity, religion or belief, sexual orientation or age. We encourage people from diverse backgrounds and with diverse characteristics to apply.
|